The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …
Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function
The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's
disease, is abundantly expressed in both the brain and periphery. Here, we present …
disease, is abundantly expressed in both the brain and periphery. Here, we present …
APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints
Z Yin, N Rosenzweig, KL Kleemann, X Zhang… - Nature …, 2023 - nature.com
The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has …
The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has …
[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …
dependent dementia. There is currently no effective treatment for AD, which may be …
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Vascular contributions to dementia and Alzheimer's disease are increasingly recognized,,,,–.
Recent studies have suggested that breakdown of the blood–brain barrier (BBB) is an early …
Recent studies have suggested that breakdown of the blood–brain barrier (BBB) is an early …
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia
The E4 allele of the apolipoprotein E gene (APOE) has been established as a genetic risk
factor for many diseases including cardiovascular diseases and Alzheimer's disease (AD) …
factor for many diseases including cardiovascular diseases and Alzheimer's disease (AD) …
Apolipoprotein E and Alzheimer's disease: findings, hypotheses, and potential mechanisms
N Koutsodendris, MR Nelson, A Rao… - Annual Review of …, 2022 - annualreviews.org
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder that involves
dysregulation of many cellular and molecular processes. It is notoriously difficult to develop …
dysregulation of many cellular and molecular processes. It is notoriously difficult to develop …